The companies will leverage Cure Genetics’ VELP platform to develop the vectors. Under the partnership, Boehringer’s experience in disease biology and gene therapy development will be combined with
Etana now has the right to sell BYVASDA in the country and in return, Innovent Biologics will receive milestones for the development and commercialisation along with double-digit royalties
The viral vector manufacturing arm of Novasep offers contract manufacturing services for vaccines and therapies to biotechnology and biopharma companies. Established over 20 years ago, the business has
The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India. Earlier, the Data and
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced,
The financing will support the full Phase 3 development of its ApoB and LDL-c lowering small molecule drug, obicetrapib. The drug, a cholesteryl ester transfer protein (CETP) inhibitor,
Under the deal, the US-based biotech company has granted an exclusive, worldwide, royalty-bearing license to Takeda Pharmaceutical pertaining to cell and non-cell therapy products that modulate targets identified
This regulatory submission was based on Phase III FIDELIO-DKD trial data, which were recently presented at the American Society of Nephrology’s (ASN) Kidney Week Reimagined 2020, and simultaneously
According to the India-based pharma company, the Sputnik V vaccine has been recommended by an independent data and safety monitoring board (DSMB) to advance to a phase 3
The Companies have agreed to jointly develop tislelizumab in these licensed countries, with Novartis responsible for regulatory submissions after a transition period and for commercialization upon regulatory approvals.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.